TCA Venture Group
VC Fund
Newport Beach, United States
TCA Venture Group is a VC fund in Newport Beach focused on Health Care and Software. TCA Venture Group is the largest angel investor group in the United States, possessing more than 300 members in five networks in Los Angeles, Orange County, San Diego, Central Coast, and the Inland Empire. Its members provide funding and guidance to more early-stage, high-growth companies in Southern California than any other investment group.Members invest in companies in a wide range of industries, including the life sciences, biotech, IT, services, retail, Internet, financial, software, media, consumer products, and tech startups. TCA as a whole gives companies more than just capital; they also provide counsel, mentoring, and access to an extensive network of potential investors, customers, strategic partners, and management talent. Tech Coast Angels has been ranked by CB Insights to be among the Top 20 Angel Groups in the US; TCA was also ranked as #1 for Network Centrality, meaning we have more connections than anyone! If you are in the game-changing business, we are here to help.
- Total investments:
- 256
- Last investment:
- Lead investor:
- 10%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries TCA Venture Group invests in
Stages TCA Venture Group invests in
Countries TCA Venture Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $600k–$4M
- Convertible Note
- $100k–$7M
Investment Focus
Industry
- Health Care 48 (19%)
- Software 47 (18%)
- Biotechnology 41 (16%)
- Medical 26 (10%)
- Information Technology 24 (9%)
Stage
- Seed 61 (24%)
- Convertible Note 48 (19%)
- Funding Round 38 (15%)
- Series A 36 (14%)
- Series B 17 (7%)
Country
- United States 203 (79%)
- Canada 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Friedman
Angel Investor, Chairman, TechCoastAngels Board of Governors
|
Angel Investor, Chairman, TechCoastAngels Board of Governors | Total investments: 2 | Find email | |
Grant Van Cleve
Chairman Emeritus
|
Chairman Emeritus | Total investments: 33 | Find email | |
Brian Coryat
Member & Angel Investor
|
Member & Angel Investor | Total investments: 0 | Find email | |
Brian Horner
President
|
President | Total investments: 3 | Find email | |
Chris Hameetman
Member
|
Member | Total investments: 3 | Find email | |
| See all 18 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Major Medical Devices
|
Major Medical Devices develops next-generation vascular devices for endovascular repair and related surgical procedures. | Venture - Series Unknown / Jan 09, 2026 | |
Nested Knowledge
|
Nested Knowledge is designing an interface that allows you to examine the data from a comprehensive literature review on research questions of interest. The interactive, nested features facilitate therapeutic comparisons, assist with research organization, and allow physicians to compare nuances across patient characteristics and outcomes. | $4.2M / Venture - Series Unknown / Jan 07, 2026 | |
EdgeX
|
Edokonta builds software that allows hospitals to track mobile equipment, such as IV pumps and ultrasounds. The company was founded in 2018 and based in San Diego, California. | $8.5M / Venture - Series Unknown / Aug 21, 2025 | |
Nob Hill Therapeutics
|
Nob Hill Therapeutics is a Delaware Corporation, founded to develop and market DryNeb, a first-in-kind dry powder nebulizer to address large pulmonary drug delivery market opportunities. The company has exclusively licensed the technology from the University of New Mexico.DryNeb™ vs. Aerosol Mist Nebulizers Compact, handheld, portable DryNeb willreplace cumbersome aerosol mist nebulizers.The pulmonary route of drug delivery has been gaining much importance in the present day, as it enables targeted drug delivery directly to the lungs for both local and systemic treatment. Pulmonary drug delivery, as a noninvasive drug administration method, is characterized by its high bioavailability and fast action. It is increasingly used in modern clinical practice for improved treatment of local as well as systemic diseases. | $3M / Series A / Aug 06, 2024 | |
Fuego
|
Fuego is a global, tech-enabled dance-inspired athleisure & lifestyle brand. Fuego's line of patented sneakers are worn by dancers in 120 countries around the world, with sole technology engineered for dancing and spinning on any surface as well as day-to-day streetwear. Take Fuego dance sneakers from the street to the dance studio, orsimply out dancing on a Friday night. The brand is endorsed by the world’s top dancers, having launched shoe collaborations with Jade Chynoweth, BDash, and ATACA. | $95.7K / Aug 01, 2024 | |
Flyte
|
Flyte is a femtech company that specializes in developing solutions to cure bladder leaks. It offers an in-home intravaginal device that both treats stress urinary incontinence and provides biofeedback to help patients strengthen pelvic floor muscles at home. | $2.3M / Seed / Apr 22, 2024 | |
NuvOx Therapeutics
|
NuvOx Pharma develops a platform for drugs that upon intravenous injection, flow through the bloodstream arriving first at the lungs to pick up oxygen and finally to hypoxic tissue where they passively deliver the oxygen. Indications for NuvOx's drug include Stroke (Phase II ready), Oncology (Phase II ready), and Sickle Cell Crisis (Phase Ibready). | $7M / Convertible Note / Sep 27, 2023 | |
Giftpack
|
Giftpack's AI-powered solution simplifies the corporate gifting process and amplifies the impact of personalized gifts. We're crafting memorable touchpoints by sending personalized gifts selected out of a curated pool of 3 million options with just one click. Our AI technology efficiently analyzes each recipient's social media,cultural background, and digital footprint to customize gift options at scale. We take care of generating, ordering, and shipping gifts worldwide. We're transforming the way people build authentic business relationships by sending smarter gifts faster with gifting CRM. | $4.3M / Seed / Sep 21, 2023 | |
ORNA
|
ORNA is an end-to-end incident response automation platform for small and midsize businesses that helps streamline or automate detection, response, and even prevention of cyberattacks on the organization's assets, all in a single tool with live 24/7 specialist support.The platform monitors cloud, on-premises, and hybrid assets (such asservers, network devices, workstations, IoT devices, and more) the organization is looking to protect around the clock, but also brings together overarching cyber incident response across all business functions, such as legal, HR, communications, and others; as well as automates evidence collection, communications, vulnerability management, and more.Main features include:Threat detection: 24/7 automated AI-led detection, triage, and containment of external and internal threats in an estimated 1/80,000s of a second.Incident response: if a threat becomes significant, ORNA invokes automated, attack scenario-specific Playbooks that cover all necessary actions across your business. ORNA guides your team across identification, containment, recovery, evidence preservation, reporting, out-of-band communications activities, and more with a single goal - reduce financial and reputation damage to your business.Threat prevention: ORNA contains NIST-based compliance, asset risk and vulnerability management, team management, IR/DR/BCP process creation, team training, and other functions designed to help you prevent threats from actualizing in the first place. | $553.5K / Angel / Aug 22, 2023 | |
Reglagene
|
Reglagene mainly engages in transforming tubulin therapy for brain diseases. It leverages its expertise in the design and development of brain-penetrant medicines to create breakthrough therapies for the safe and effective treatment of brain diseases. | Aug 01, 2023 | |
| See all 256 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does TCA Venture Group invest in?
TCA Venture Group invests primarily in Health Care, Software and Biotechnology startups, most often at Seed and Convertible Note stage. Most of the 256 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is TCA Venture Group's check size?
TCA Venture Group typically joins rounds of $600k–$4M at Seed and $100k–$7M at Convertible Note. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TCA Venture Group participates in.
How do I contact TCA Venture Group?
Public channels for TCA Venture Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TCA Venture Group?
The team at TCA Venture Group includes David Friedman (Angel Investor, Chairman, TechCoastAngels Board of Governors), Grant Van Cleve (Chairman Emeritus) and Brian Coryat (Member & Angel Investor), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
